A prospective examination of octreotide-induced gall-bladder changes in acromegaly

R. C. Eastman, R. F. Arakaki, T. Shawker, R. Schock, Paris Roach, R. J. Comi, P. Gorden

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: We wished to determine the effects of octreotide acetate, a somatostatin analogue, on gall-bladder function during treatment of acromegaly. Design: We used a prospective, open label trial of somatostatin analogue. Patients: Seventeen patients with acromegaly took part. Measurements: Ultrasonographic evaluation of gallbladder contents were performed pretreatment, after 1 month, and subsequently at intervals of 3-6 months. Results: Non-shadowing floating echogenic particles were observed in the gall-bladder in 12 of 17 patients after (mean ± SEM) 2.5 ± 0.6 months of treatment. During long-term treatment (mean 20.8 ± 4.3, median 13, range 1-59 months), ultrasound evidence for cholelithiasis was observed in four patients after 20 ± 4 months (range 4.2-43) months of octreotide therapy. No symptoms of biliary tract disease have been observed. Duration of acromegaly, average GH, average IGF-I, gender, age at entry, dose of analogue, and concurrent use of non-steroidal anti-inflammatory drugs did not affect the occurrence of sludge or gallstones. Conclusions: Formation of non-shadowing, floating echogenic particles occurs commonly during the first 6 months of treatment with octreotide acetate. Cholelithiasis is a risk of long-term treatment.

Original languageEnglish (US)
Pages (from-to)265-269
Number of pages5
JournalClinical Endocrinology
Volume36
Issue number3
StatePublished - 1992
Externally publishedYes

Fingerprint

Acromegaly
Octreotide
Urinary Bladder
Cholelithiasis
Somatostatin
Therapeutics
Biliary Tract Diseases
Gallstones
Sewage
Gallbladder
Insulin-Like Growth Factor I
Anti-Inflammatory Agents
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology

Cite this

Eastman, R. C., Arakaki, R. F., Shawker, T., Schock, R., Roach, P., Comi, R. J., & Gorden, P. (1992). A prospective examination of octreotide-induced gall-bladder changes in acromegaly. Clinical Endocrinology, 36(3), 265-269.

A prospective examination of octreotide-induced gall-bladder changes in acromegaly. / Eastman, R. C.; Arakaki, R. F.; Shawker, T.; Schock, R.; Roach, Paris; Comi, R. J.; Gorden, P.

In: Clinical Endocrinology, Vol. 36, No. 3, 1992, p. 265-269.

Research output: Contribution to journalArticle

Eastman, RC, Arakaki, RF, Shawker, T, Schock, R, Roach, P, Comi, RJ & Gorden, P 1992, 'A prospective examination of octreotide-induced gall-bladder changes in acromegaly', Clinical Endocrinology, vol. 36, no. 3, pp. 265-269.
Eastman RC, Arakaki RF, Shawker T, Schock R, Roach P, Comi RJ et al. A prospective examination of octreotide-induced gall-bladder changes in acromegaly. Clinical Endocrinology. 1992;36(3):265-269.
Eastman, R. C. ; Arakaki, R. F. ; Shawker, T. ; Schock, R. ; Roach, Paris ; Comi, R. J. ; Gorden, P. / A prospective examination of octreotide-induced gall-bladder changes in acromegaly. In: Clinical Endocrinology. 1992 ; Vol. 36, No. 3. pp. 265-269.
@article{7755b2fc21c840b49535ae38b8b769cd,
title = "A prospective examination of octreotide-induced gall-bladder changes in acromegaly",
abstract = "Objective: We wished to determine the effects of octreotide acetate, a somatostatin analogue, on gall-bladder function during treatment of acromegaly. Design: We used a prospective, open label trial of somatostatin analogue. Patients: Seventeen patients with acromegaly took part. Measurements: Ultrasonographic evaluation of gallbladder contents were performed pretreatment, after 1 month, and subsequently at intervals of 3-6 months. Results: Non-shadowing floating echogenic particles were observed in the gall-bladder in 12 of 17 patients after (mean ± SEM) 2.5 ± 0.6 months of treatment. During long-term treatment (mean 20.8 ± 4.3, median 13, range 1-59 months), ultrasound evidence for cholelithiasis was observed in four patients after 20 ± 4 months (range 4.2-43) months of octreotide therapy. No symptoms of biliary tract disease have been observed. Duration of acromegaly, average GH, average IGF-I, gender, age at entry, dose of analogue, and concurrent use of non-steroidal anti-inflammatory drugs did not affect the occurrence of sludge or gallstones. Conclusions: Formation of non-shadowing, floating echogenic particles occurs commonly during the first 6 months of treatment with octreotide acetate. Cholelithiasis is a risk of long-term treatment.",
author = "Eastman, {R. C.} and Arakaki, {R. F.} and T. Shawker and R. Schock and Paris Roach and Comi, {R. J.} and P. Gorden",
year = "1992",
language = "English (US)",
volume = "36",
pages = "265--269",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A prospective examination of octreotide-induced gall-bladder changes in acromegaly

AU - Eastman, R. C.

AU - Arakaki, R. F.

AU - Shawker, T.

AU - Schock, R.

AU - Roach, Paris

AU - Comi, R. J.

AU - Gorden, P.

PY - 1992

Y1 - 1992

N2 - Objective: We wished to determine the effects of octreotide acetate, a somatostatin analogue, on gall-bladder function during treatment of acromegaly. Design: We used a prospective, open label trial of somatostatin analogue. Patients: Seventeen patients with acromegaly took part. Measurements: Ultrasonographic evaluation of gallbladder contents were performed pretreatment, after 1 month, and subsequently at intervals of 3-6 months. Results: Non-shadowing floating echogenic particles were observed in the gall-bladder in 12 of 17 patients after (mean ± SEM) 2.5 ± 0.6 months of treatment. During long-term treatment (mean 20.8 ± 4.3, median 13, range 1-59 months), ultrasound evidence for cholelithiasis was observed in four patients after 20 ± 4 months (range 4.2-43) months of octreotide therapy. No symptoms of biliary tract disease have been observed. Duration of acromegaly, average GH, average IGF-I, gender, age at entry, dose of analogue, and concurrent use of non-steroidal anti-inflammatory drugs did not affect the occurrence of sludge or gallstones. Conclusions: Formation of non-shadowing, floating echogenic particles occurs commonly during the first 6 months of treatment with octreotide acetate. Cholelithiasis is a risk of long-term treatment.

AB - Objective: We wished to determine the effects of octreotide acetate, a somatostatin analogue, on gall-bladder function during treatment of acromegaly. Design: We used a prospective, open label trial of somatostatin analogue. Patients: Seventeen patients with acromegaly took part. Measurements: Ultrasonographic evaluation of gallbladder contents were performed pretreatment, after 1 month, and subsequently at intervals of 3-6 months. Results: Non-shadowing floating echogenic particles were observed in the gall-bladder in 12 of 17 patients after (mean ± SEM) 2.5 ± 0.6 months of treatment. During long-term treatment (mean 20.8 ± 4.3, median 13, range 1-59 months), ultrasound evidence for cholelithiasis was observed in four patients after 20 ± 4 months (range 4.2-43) months of octreotide therapy. No symptoms of biliary tract disease have been observed. Duration of acromegaly, average GH, average IGF-I, gender, age at entry, dose of analogue, and concurrent use of non-steroidal anti-inflammatory drugs did not affect the occurrence of sludge or gallstones. Conclusions: Formation of non-shadowing, floating echogenic particles occurs commonly during the first 6 months of treatment with octreotide acetate. Cholelithiasis is a risk of long-term treatment.

UR - http://www.scopus.com/inward/record.url?scp=0026559186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026559186&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 265

EP - 269

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -